At present, drugs for the treatment of cancer-induced muscle atrophy include natural compounds such as eicosapentaenoic acid [40,41], resveratrol [42,43], ghrelin [44], enzyme inhibitors such as Cox2 inhibitors such as celecoxib, meloxicam [45,46,47], and phosphodiesterase inhibitors such as torbafylline, pentoxifylline [48,49], beta-adrenergic receptor agonists (formoterol) [50,51], and anti-cytokine agents, which include anti-TNFα, thalidomide [52,53,54]. The gene discussed is TNF; the disease is cancer.